Crucell corporate brochure (PDF)

24
Our business – Technologies
The PERCIVIA PER.C6® Development Center
is designed to further develop the PER.C6®
cell line and to provide turnkey solutions for
licensees utilizing the PER.C6® human cell
line to produce pharmaceutical proteins.
PERCIVIA PER.C6® Development Center
In September 2010, Crucell and Royal DSM announced the expansion
of activities in their existing joint venture, the PERCIVIA PER.C6®
Development Center (Cambridge, Massachusetts, US), to transform
the company from a development center into a full biopharmaceutical
company for the development of PER.C6®-based biobetter proteins
and monoclonal antibodies as well as global licensing of the PER.C6®
human cell line for production of third party monoclonal antibodies
and other proteins. The joint venture, in which DSM and Crucell each
hold an equal equity share, will be known as PERCIVIA LLC. The joint
venture will broaden its scope and will focus on proprietary development
of PER.C6®-based biobetter proteins and monoclonal antibodies,
initially to early clinical stages.
AdVac® technology
AdVac® technology involves the development and manufacture
of novel vectors (gene transport vehicles) made from adenoviruses
(harmless cold viruses) that very rarely infect humans, such as Ad35.
Genetic material encoding for viruses, parasites or bacteria can be
inserted into these vectors to make novel vaccines against a broad
range of human pathogens, or the vectors can be used to make
gene therapy products.
www.crucell.com
AdVac® technology is a powerful vector system, especially when
coupled with Crucell’s PER.C6® technology, which unlike any other
cell line does not allow replication-competent adenoviruses to form
during the production of replication-deficient vectors.
AdVac® technology is based on adenoviruses that very rarely infect
humans, whereas other adenovirus vectors are based on viruses that are
widespread in human populations—and therefore much more likely to
encounter pre-existing immunity. By circumventing pre-existing immune
responses against the adenovirus vector, AdVac®-based vaccines allow
accurate dose control and are potentially more effective than other
adenoviral vector vaccines.
AdVac®-based vectors share the advantages of the widely used
adenovirus vectors, such as scalable production, high yields and the
ability to mediate a strong T-cell immune response.